Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Core Insights - Dermata Therapeutics is advancing its Phase 3 STAR-1 trial for XYNGARI™, a novel topical treatment for moderate-to-severe acne, with topline results expected by the end of March 2025 [1][2] Company Overview - Dermata Therapeutics is a late-stage biotechnology company focused on treating medical and aesthetic skin conditions, with its lead product candidate being XYNGARI™, derived from a freshwater sponge [8] - The company is headquartered in San Diego, California, and is also developing a second product candidate, DMT410, for needle-free delivery of botulinum toxin [8] Product Details - XYNGARI™ is designed as a once-weekly topical treatment that targets the root causes of acne through multiple mechanisms of action, including reducing inflammation and unclogging pores [3][5] - The Phase 3 STAR-1 trial enrolled 520 patients aged 9 years and older in the U.S. and Latin America, focusing on the efficacy, safety, and tolerability of XYNGARI™ [4] Market Context - Over 30 million acne patients seek treatment annually in the U.S., with a significant unmet need for effective acne therapies [7] - Acne affects approximately 85% of U.S. teenagers and can persist into adulthood, leading to social stigma and lowered self-esteem [7]